Table 3 Univariate and multivariate analyses of the impact on survival of clinical features along with logged CRP, IL-6 and GM-CSF levels

From: Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma

Univariate

Hazard ratio (95% CI)

P- value

Response: PD v SD/PR

8.61 (2.97–24.98)

<0.0001

Age

0.98 (0.95–1.02)

0.40

Stage: locally advanced vs metastatic

0.66 (0.32–1.37)

0.26

ECOG 0 v 1

1.02 (0.45–2.28)

 

ECOG 1 v 2

0.42 (0.14–1.26)

0.22

ECOG 0 v 2

0.41 (0.15–1.17)

 

Log CA19-9: baseline

1.33 (1.10–1.61)

0.004

Log CRP: baseline

1.76 (1.18–2.65)

0.006

Log CRP: post treatment

1.38 (0.89–2.13)

0.16

Log CRP: difference

0.75 (0.46–1.23)

0.25

Log IL-6: baseline

0.73 (0.47–1.14)

0.16

Log IL-6: post treatment

0.84 (0.61–1.15)

0.27

Log Il-6: difference

1.05 (0.64–1.75)

0.84

GM-CSF: baseline

0.75 (0.33–1.71)

0.50

GM-CSF: post treatment

0.81 (0.36–1.81)

0.60

Multivariate

Log CA19-9: baseline

1.30 (1.07–1.59)

0.009

Log CRP: baseline

1.55 (1.00–2.39)

0.049

  1. Abbreviations: CA19-9=carbohydrate antigen-19-9; CI=confidence interval; CRP=C-reactive protein; ECOG=Eastern Cooperative Oncology Group; GM-CSF=granulocyte macrophage-colony-stimulating factor; IL-6=interleukin 6; PD=progressive disease; PR=partial response; SD=stable disease. The bold values are statistically significant.